Hyderabad-based Dr. Reddy’s Laboratories Limited has reportedly launched a generic version of Ciprodex (ciprofloxacin 0.3% and dexamethasone 0.1%) Otic Suspension in the U. S market, after getting approval from the US FDA (Food and Drug Administration).
Ciprodex is generally recommended for the treatment of infections developed by susceptible isolates of established microorganisms under the specific conditions of AOM (Acute Otitis Media) in pediatric and AOE( Acute Otitis Externa) in adult, pediatric, and elderly patients.
Marc Kikuchi, who is the CEO of North America Generics business at Dr. Reddy’s Laboratories seemed to be rather satisfied with the first-to-market product launch and has appreciated the firm’s commitment to bringing affordable generic medicine to patients. The move highlights the firm’s efforts to expand the depth of portfolio with the first otic suspension dosage form, he said.
For the last 12 months, according to IQVIA Health, the Ciprodex ® brand had recorded US revenue of roughly $453 million MAT. Dr. Reddy’s Ciprofloxacin 0.3% and Dexamethasone 0.1% Otic Suspension, USP, will be available as 7.5 mL fill in a 10 mL bottle.
For the record, Dr. Reddy’s provides a range of products and facilities including APIs, biosimilars, generics, personalized pharmaceutical services, and distinguished formulations. Their primary medical areas of focus are cardiovascular, diabetology, pain management, gastrointestinal, oncology, and dermatology.
Dr. Reddy works in industries across the globe with primary markets in the USA, India, Europe, and Russia & CIS countries.
Earlier at July-end, Dr. Reddy’s Laboratories stocks reached a record Rs 4,224, up 4 percent of the on BSE after a stronger than anticipated Rs 579 crore net profit (Q1FY21) posted based on solid sales expansion in the April-June period. An income of Rs 663 crore was earned by the Pharmaceutical Firm in the Year-ago time. On 10 June 2020, the stock reached its previous high of Rs 4189.35.